武田完成向Cheplapharm出售部分非核心资产

2021-01-06 国际文传 国际文传

武田药品工业株式会社今天宣布完成其先前宣布的向Cheplapharm出售部分处方药品阵容的交易,交易总价值为5.62亿美元。

武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE:4502/NYSE:TAK)(“武田”)今天宣布完成其先前宣布的向Cheplapharm出售部分处方药品阵容的交易,交易总价值为5.62亿美元1。该产品阵容包括16种主要在欧洲销售的处方药品,是武田欧洲和加拿大事业部的一部分。该剥离协议最初于2020年9月宣布。

剥离的产品阵容涵盖各种治疗类别的非核心处方药品,包括血管/代谢和抗炎产品以及钙。上述产品旨在满足这些国家关键的患者需求,但同时又不属于武田五大核心业务领域:胃肠病学(GI)、罕见病、血浆衍生疗法、肿瘤学和神经科学,这与武田的长期增长战略相一致。

武田始终专注于执行其长期增长战略,以优化我们在关键业务领域的业务组合,通过在上述领域提供创新治疗药物来简化我们的运营,以更好地服务于患者。

公司计划将出售所得款项用于减少债务,并加速去杠杆化,以实现其在2021-2023财年内净债务/经调整EBITDA翻倍的目标。

2020年,武田的资产剥离战略保持强劲势头,超过其剥离100亿美元非核心资产的目标,2019年1月迄今宣布11项交易,累计总价值高达约116亿美元,其中包括以下剥离协议:

  • Takeda Consumer Healthcare Company Limited出售给由The Blackstone Group Inc.及其附属公司管理基金控制的Oscar A-Co KK,总价值约2420亿日元(合23亿美元)。
  • 成长与新兴市场事业部内的其他非核心产品阵容资产,总计高达约23亿美元,分别出售给五位买家2
  • 在欧洲的部分OTC和非核心资产出售给Orifarm,价格高达约6.7亿美元。
  • TachoSil纤维蛋白密封剂贴片出售给Corza Health, Inc.,价格约3.5亿欧元。

关于武田药品工业株式会社

武田药品工业株式(TSE:4502/NYSE:TAK)是一家总部位于日本的以价值观为基础的研发驱动型跨国生物制药翘楚,秉承我们对患者、员工和地球的承诺,致力于发现和交付转变命运的药品。武田的研究努力专注于四大治疗领域:肿瘤学、罕见遗传病和血液学、神经科学和胃肠病学(GI)。我们同时在血浆衍生治疗药物和疫苗领域进行针对性研发投入。我们正在专注于开发有助于改善患者生活的高度创新的药品,努力推进新治疗选择的前沿,并充分利用我们增强的协作研发引擎和能力,以研制强大且模式多样的后续产品线。

我们的员工致力于改善患者的生活品质,在约80个国家与我们的合作伙伴在医疗保健领域携手合作。

如需了解进一步信息,请访问https://www.takeda.com

重要提示

就本文而言,“新闻稿”指本文件、任何口头陈述、任何问答会议,以及武田药品工业株式会社(“武田”)就本新闻稿相关内容进行讨论或分发的任何书面或口头资料。本新闻稿(包括任何口头简报和与此有关的任何问答)并非是也不构成、代表或形成任何出价购买、以及收购、注册、交换、销售或处置任何证券的任何要约、邀请或征集,或在任何司法管辖区征集任何投票或批准之一部分。不得凭借本新闻稿公开发售任何股票。除非根据美国《1933年证券法》及其修订进行登记或由此取得豁免,否则不得在美国配售任何证券。本新闻稿(连同任何可能向接收方提供的进一步信息)仅用于为接收方提供信息参考用途(并非用于评估任何投资、收购、处置或任何其他交易)。任何不遵守上述限制的行为可能会违反适用证券法。

武田通过投资直接或间接所持有公司均为独立的实体。在本新闻稿中,有时出于方便的目的,使用“武田”作为武田及其子公司的统称。同样,像“我们”(主语和宾语形式)和“我们的”这类词语也是子公司的统称或代表公司的员工。这些表述也被用于没有实际意义、不涉及某个特定的公司或某些公司的场合。

前瞻性陈述

本新闻稿及与之相关的所分发的任何资料可能含有与武田未来业务、未来状况和运营业绩有关的前瞻性陈述、看法或意见,包括武田的预估、预测、目标和计划。前瞻性陈述常常包含但不限于下列措辞,例如“目标”、“计划”、“认为”、“希望”、“继续”、“预计”、“旨在”、“打算”、 “确保”、“将”、“可能”、“应”、“会”、“或许”、“预期”、“估计”、“预测”或类似表述或其否定形式。这些前瞻性陈述基于对众多重要因素的假设,包括下列可能导致实际结果与前瞻性陈述所表达或暗示的结果大相径庭的因素:武田全球业务所面临的经济形势,包括日本和美国的宏观经济环境;竞争压力和发展情况;适用法律法规的变动;产品开发项目的成功或失败;监管当局的决策或做出决策的时机;利率和汇率波动;有关已售产品或候选产品安全或功效的索赔或疑问;诸如新型冠状病毒大流行之类的健康危机对武田及其顾客和供应商的影响,包括武田经营所在国家的外国政府或其业务的其他方面;已收购公司的合并后整合努力的时机和影响;能否剥离对武田运营非核心的资产和任何此类剥离的时机;以及武田Form 20-F最新年报以及武田向美国证券交易委员会提交的其他报告中确认的其他因素,具体请查阅武田网站https://www.takeda.com/investors/reports/sec-filings/www.sec.gov。除非法律或证券交易规则所要求,武田没有义务更新本新闻稿中的任何前瞻性陈述或公司可能发布的任何其他前瞻性陈述。历史业绩并不能代表未来业绩,而且本新闻稿中的武田结果并不能指代,也并非是武田未来结果的预估、预测或推测。

1基于4.75亿欧元的协议价格和20209月协议签订时的汇率

2包括在中国的非核心产品出售给Hasten Biopharmaceutic (China)的协议,在拉丁美洲的部分非核心产品出售给Hypera S.A.的协议仍有待签署;已完成下列地区非核心资产的出售:俄罗斯-独联体地区给STADA,近东、中东和非洲地区给Acino,亚太地区给Celltrion Inc.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1783066, encodeId=199f1e83066bf, content=<a href='/topic/show?id=b8ab46246e' target=_blank style='color:#2F92EE;'>#CHEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4624, encryptionId=b8ab46246e, topicName=CHEP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Fri Jul 16 06:51:50 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787700, encodeId=97c51e877009c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Feb 22 09:51:50 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734678, encodeId=950c1e3467897, content=<a href='/topic/show?id=2239106951c' target=_blank style='color:#2F92EE;'>#LAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10695, encryptionId=2239106951c, topicName=LAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06de33803044, createdName=LSJ122, createdTime=Sun Mar 21 12:51:50 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919486, encodeId=0c8d91948676, content=^_^, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210209/c24ce6bb97bb4de0968e69be1f6d3ca4/93f7c058bb894fc39a47081bc5283bc1.jpg, createdBy=e3945412064, createdName=Wlgank, createdTime=Sun Jan 24 17:15:30 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517263, encodeId=efbd151e263b5, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Fri Jan 08 03:51:50 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914072, encodeId=60089140e2b9, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c765450508, createdName=ms1000000737789139, createdTime=Wed Jan 06 13:27:41 CST 2021, time=2021-01-06, status=1, ipAttribution=)]
    2021-07-16 july_975
  2. [GetPortalCommentsPageByObjectIdResponse(id=1783066, encodeId=199f1e83066bf, content=<a href='/topic/show?id=b8ab46246e' target=_blank style='color:#2F92EE;'>#CHEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4624, encryptionId=b8ab46246e, topicName=CHEP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Fri Jul 16 06:51:50 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787700, encodeId=97c51e877009c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Feb 22 09:51:50 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734678, encodeId=950c1e3467897, content=<a href='/topic/show?id=2239106951c' target=_blank style='color:#2F92EE;'>#LAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10695, encryptionId=2239106951c, topicName=LAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06de33803044, createdName=LSJ122, createdTime=Sun Mar 21 12:51:50 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919486, encodeId=0c8d91948676, content=^_^, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210209/c24ce6bb97bb4de0968e69be1f6d3ca4/93f7c058bb894fc39a47081bc5283bc1.jpg, createdBy=e3945412064, createdName=Wlgank, createdTime=Sun Jan 24 17:15:30 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517263, encodeId=efbd151e263b5, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Fri Jan 08 03:51:50 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914072, encodeId=60089140e2b9, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c765450508, createdName=ms1000000737789139, createdTime=Wed Jan 06 13:27:41 CST 2021, time=2021-01-06, status=1, ipAttribution=)]
    2021-02-22 jj000001
  3. [GetPortalCommentsPageByObjectIdResponse(id=1783066, encodeId=199f1e83066bf, content=<a href='/topic/show?id=b8ab46246e' target=_blank style='color:#2F92EE;'>#CHEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4624, encryptionId=b8ab46246e, topicName=CHEP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Fri Jul 16 06:51:50 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787700, encodeId=97c51e877009c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Feb 22 09:51:50 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734678, encodeId=950c1e3467897, content=<a href='/topic/show?id=2239106951c' target=_blank style='color:#2F92EE;'>#LAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10695, encryptionId=2239106951c, topicName=LAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06de33803044, createdName=LSJ122, createdTime=Sun Mar 21 12:51:50 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919486, encodeId=0c8d91948676, content=^_^, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210209/c24ce6bb97bb4de0968e69be1f6d3ca4/93f7c058bb894fc39a47081bc5283bc1.jpg, createdBy=e3945412064, createdName=Wlgank, createdTime=Sun Jan 24 17:15:30 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517263, encodeId=efbd151e263b5, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Fri Jan 08 03:51:50 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914072, encodeId=60089140e2b9, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c765450508, createdName=ms1000000737789139, createdTime=Wed Jan 06 13:27:41 CST 2021, time=2021-01-06, status=1, ipAttribution=)]
    2021-03-21 LSJ122
  4. [GetPortalCommentsPageByObjectIdResponse(id=1783066, encodeId=199f1e83066bf, content=<a href='/topic/show?id=b8ab46246e' target=_blank style='color:#2F92EE;'>#CHEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4624, encryptionId=b8ab46246e, topicName=CHEP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Fri Jul 16 06:51:50 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787700, encodeId=97c51e877009c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Feb 22 09:51:50 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734678, encodeId=950c1e3467897, content=<a href='/topic/show?id=2239106951c' target=_blank style='color:#2F92EE;'>#LAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10695, encryptionId=2239106951c, topicName=LAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06de33803044, createdName=LSJ122, createdTime=Sun Mar 21 12:51:50 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919486, encodeId=0c8d91948676, content=^_^, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210209/c24ce6bb97bb4de0968e69be1f6d3ca4/93f7c058bb894fc39a47081bc5283bc1.jpg, createdBy=e3945412064, createdName=Wlgank, createdTime=Sun Jan 24 17:15:30 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517263, encodeId=efbd151e263b5, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Fri Jan 08 03:51:50 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914072, encodeId=60089140e2b9, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c765450508, createdName=ms1000000737789139, createdTime=Wed Jan 06 13:27:41 CST 2021, time=2021-01-06, status=1, ipAttribution=)]
    2021-01-24 Wlgank

    ^_^

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1783066, encodeId=199f1e83066bf, content=<a href='/topic/show?id=b8ab46246e' target=_blank style='color:#2F92EE;'>#CHEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4624, encryptionId=b8ab46246e, topicName=CHEP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Fri Jul 16 06:51:50 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787700, encodeId=97c51e877009c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Feb 22 09:51:50 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734678, encodeId=950c1e3467897, content=<a href='/topic/show?id=2239106951c' target=_blank style='color:#2F92EE;'>#LAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10695, encryptionId=2239106951c, topicName=LAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06de33803044, createdName=LSJ122, createdTime=Sun Mar 21 12:51:50 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919486, encodeId=0c8d91948676, content=^_^, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210209/c24ce6bb97bb4de0968e69be1f6d3ca4/93f7c058bb894fc39a47081bc5283bc1.jpg, createdBy=e3945412064, createdName=Wlgank, createdTime=Sun Jan 24 17:15:30 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517263, encodeId=efbd151e263b5, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Fri Jan 08 03:51:50 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914072, encodeId=60089140e2b9, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c765450508, createdName=ms1000000737789139, createdTime=Wed Jan 06 13:27:41 CST 2021, time=2021-01-06, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1783066, encodeId=199f1e83066bf, content=<a href='/topic/show?id=b8ab46246e' target=_blank style='color:#2F92EE;'>#CHEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4624, encryptionId=b8ab46246e, topicName=CHEP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Fri Jul 16 06:51:50 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787700, encodeId=97c51e877009c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Feb 22 09:51:50 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734678, encodeId=950c1e3467897, content=<a href='/topic/show?id=2239106951c' target=_blank style='color:#2F92EE;'>#LAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10695, encryptionId=2239106951c, topicName=LAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06de33803044, createdName=LSJ122, createdTime=Sun Mar 21 12:51:50 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919486, encodeId=0c8d91948676, content=^_^, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210209/c24ce6bb97bb4de0968e69be1f6d3ca4/93f7c058bb894fc39a47081bc5283bc1.jpg, createdBy=e3945412064, createdName=Wlgank, createdTime=Sun Jan 24 17:15:30 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517263, encodeId=efbd151e263b5, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Fri Jan 08 03:51:50 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914072, encodeId=60089140e2b9, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c765450508, createdName=ms1000000737789139, createdTime=Wed Jan 06 13:27:41 CST 2021, time=2021-01-06, status=1, ipAttribution=)]
    2021-01-06 ms1000000737789139

    已学习

    0

相关资讯

医保新规今日实施:八类药品不纳入基本医保

今日(9月1日),国家医保局曾于7月31日公布《基本医疗保险用药管理暂行办法》(以下简称暂行办法)正式实施。

详解医保目录调整 调入药品不仅“物美”还应“价廉”

医保目录调整大幕拉开,谁走谁留,规则终于敲定。

《隐秘的角落》中藏着哪些药品安全隐患?

近日,社会悬疑题材网剧《隐秘的角落》热播,整个网剧的故事架构、人物设定、叙事节奏吸引了大量的观众。其中女主人公本应服用治疗贫血的药物却误服了放在分装药盒中的降糖药品,最终在游泳期间发生低血糖溺水身亡的

“一支药70万元”“国外便宜国内贵”?聚焦“天价”罕见病药

日前,网络流传“治疗罕见病‘脊髓性肌萎缩症’特效药物需‘70万元一支’天价,且国内价格远高于国外”,引发社会关注。

喜讯!国家采购“以量换价” 55种药品降价了!

第三批国家带量采购本月执行,55种药品、191个产品中选,涉及高血压、糖尿病、恶性肿瘤等药品品种,平均降价53%!以化疗用药卡培他滨为例,药品由原来的每片15元降至3元多。国家集采怎样通过&ldquo

两类情况药品临床期间即可申请批准!《药品附条件批准上市技术指导原则(试行)》即日实施

昨日(11月19日),国家药监局CDE发布关于《药品附条件批准上市技术指导原则(试行)》(以下简称指导原则)的通告,根据通告,《指导原则》自发布之日起正式施行。